Back
ESC2025 Premium Access

Impact of real-world off-label dose of apixaban on long-term clinical outcomes in heart failure patients with atrial fibrillation and end stage kidney disease

Session: Atrial fibrillation management: from anticoagulation to SGLT2 inhibitors
Topic: Oral Anticoagulation
Speaker: Doctor S. Im (Pusan, KR)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Sung Il Im

kosin university gospel hospital, Pusan (Korea (Republic of))
0 follower

2 more presentations in this session

Impact of cardiac damage on cardioversion success in patients with atrial fibrillation and heart failure with preserved ejection fraction

Speaker: Doctor P. Wilke (Duesseldorf, DE)

Access
Abstract
Slides
Video
Like
Thumbnail

Effect of glucagon-like peptide-1 receptor agonists on atrial fibrillation incidence: a systematic review and meta-analysis

Speaker: Mr K. Banerjee (London, GB)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Atrial fibrillation management: from anticoagulation to SGLT2 inhibitors

Speakers: Doctor S. Im, Doctor P. Wilke, Mr K. Banerjee
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources